Milestone Pharmaceuticals Inc
MIST1.840USD
-0.010-0.54%
終値 11/04, 16:00（ET）15分遅れの株価
98.43M時価総額
損失額直近12ヶ月PER
詳細情報 Milestone Pharmaceuticals Inc 企業名
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Milestone Pharmaceuticals Incの企業情報
企業コードMIST
会社名Milestone Pharmaceuticals Inc
上場日May 09, 2019
最高経営責任者「CEO」Mr. Joseph Oliveto
従業員数33
証券種類Ordinary Share
決算期末May 09
本社所在地420-1111 boul. Dr.-Frederik-Philips
都市MONTREAL
証券取引所NASDAQ Global Select Consolidated
国Canada
郵便番号H4M 2X6
電話番号15143360444
ウェブサイトhttps://www.milestonepharma.com
企業コードMIST
上場日May 09, 2019
最高経営責任者「CEO」Mr. Joseph Oliveto
Milestone Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Independent Director
Independent Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Thu, Oct 30
更新時刻: Thu, Oct 30
株主統計
種類
株主統計
株主統計
比率
Trails Edge Capital Partners LP
6.27%
Simplify Asset Management Inc
3.33%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
2.11%
他の
82.38%
株主統計
株主統計
比率
Trails Edge Capital Partners LP
6.27%
Simplify Asset Management Inc
3.33%
Oliveto (Joseph Gerard)
2.95%
RTW Investments L.P.
2.95%
Propel Bio Management, LLC
2.11%
他の
82.38%
種類
株主統計
比率
Investment Advisor
12.62%
Individual Investor
3.61%
Investment Advisor/Hedge Fund
3.03%
Hedge Fund
2.58%
Venture Capital
2.30%
Research Firm
2.16%
Bank and Trust
0.02%
他の
73.68%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
99
19.30M
22.71%
-5.65M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
2023Q2
108
21.35M
63.87%
-11.78M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Trails Edge Capital Partners LP
5.33M
6.27%
+5.33M
--
Jul 14, 2025
Simplify Asset Management Inc
990.00K
1.16%
+140.00K
+16.47%
Jun 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
RTW Investments L.P.
2.51M
2.95%
--
--
Jun 30, 2025
Propel Bio Management, LLC
1.79M
2.11%
+340.00K
+23.42%
Jun 30, 2025
Alta Fundamental Advisers LLC
1.40M
1.65%
-28.50K
-2.00%
Jun 30, 2025
BML Capital Management LLC
1.14M
1.34%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
817.82K
0.96%
-148.10K
-15.33%
Jun 30, 2025
TD Securities, Inc.
750.00K
0.88%
--
--
Jun 30, 2025
Lion Point Capital, L.P.
548.81K
0.65%
--
--
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sun, Nov 2
更新時刻: Sun, Nov 2
銘柄名
比率
Simplify Propel Opportunities ETF
8.56%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
比率8.56%
SPDR S&P International Small Cap ETF
比率0.01%
Avantis US Small Cap Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
